

Curriculum vitae – Arne Kolstad

Personal information

First name, Surname:	Arne Kolstad		
Date of birth:	4 th December 1958	Sex:	Male
Nationality:	Norwegian		

Education

Year	Faculty/department - University/institution - Country
1989	Ph.D. (Dr. med.) Medical faculty, University of Tromsø, Norway
1984	M.D. Faculty of Medicine, University of Tromsø, Norway

Positions - current and previous

(Academic sector/research institutes/industrial sector/public sector/other)

Year	Job title – Employer - Country
2022-present	Professor of Medicine, Norwegian Univ Tech (NTNU)
2021-present	Senior consultant, Cancer clinic Innlandet Lillehammer Gjøvik
2020-2021	Senior consultant Dept of Oncology, The Norwegian Radium Hospital
2013-2019	Senior consultant Dept of Oncology, The Norwegian Radium Hospital 50% and clinical researcher Norwegian Cancer Society 50%
2003-2013	Senior consultant Dept of Oncology, The Norwegian Radium Hospital
1995-2003	Senior consultant Dept of Oncology, Tromsø University Hospital
1993-1995	Residency Dept of Oncology The Norwegian Radium Hospital
1990-1993	Residency Dept of Oncology/Internal Medicine Tromsø University Hospital
1989-1990	GP Internship
1986-1989	Research Fellow, Institute of immunology, University of Tromsø
1985-1986	Internship
1984-1985	Research fellow, Dept of Immunology, University of Tromsø

Project management experience

(Academic sector/research institutes/industrial sector/public sector/other. Please list the most relevant.)

Year	Project owner - Project - Role - Funder
2007-2020	Chairman of Norwegian Lymphoma Group
2014-2018	Chairman of OUH Focus Area "Cancer Immunotherapy"
2012-2014	Leader of research group «Immunotherapy in Cancer» OUH
2013-2019	Senior Partner in KG Jebsen Center for Cancer Immunotherapy

Supervision of students

Master's students	Ph.D. students	University/institution - Country
3	8	Universities of Tromsø and Oslo, Norway

Other relevant professional experiences

Description - Role
Visiting professor , Stanford University California, US 2006-2007
Visiting researcher, University of Michigan, US 1998-1999
Head, Department of Oncology Tromsø University Hospital 2000-2001
Associate professor, Institute of Clinical Medicine, University of Tromsø
Member, Speciality committee for Oncology
Member, Reference group lymphoid malignancies, Norwegian Cancer Registry
Member, Nordic Mantle cell lymphoma Group
Chairman, Norwegian Lymphoma Group 2007-2020
Chairman, National group for development of "Pakkeforløp lymfom" 204
Board Member, Onkologisk Forum
Member, National Stem cell Group, OUH Rikshospitalet
Winner of Ragnar Mørks Cancer Research Award, Norweg Radium Hospital 2014
Winner of award from Oslo University Hospital for outstanding original article 2014
Awarded Researcher of the Month by Helse Sør-Øst Sept 2015

Principal investigator of 17 clinical trials, some selected below

National coordinating investigator for Nordic Phase II multicenter studies (MCL-1, MCL-2 and MCL-3) in mantle cell lymphoma. Completed and published

Chairman and principal investigator of exploratory single center study with sequential intratumoral immunotherapy (Lymvac-1) in follicular lymphoma. Completed and published

National coordinating investigator in Nordic Phase II study with Bendamustine, Lenalidomide and Rituximab (LenaBerit) in mantle cell lymphoma. Completed and published

National coordinating investigator in Nordic phase II study with Ibrutinib, Lenalidomide and Rituximab (Philemon) in mantle cell lymphoma. Completed and published

National coordinating investigator in European multicenter phase III study with Ibrutinib (TRIANGLE) in mantle cell lymphoma. Completed

National coordinating investigator in Nordic phase I/II study with Venetoclax, Lenalidomide and Rituximab (VALERIA) for patients with relapsed mantle cell lymphoma. Ongoing

Principal investigator in Nordic/UK phase III study with R-chemo versus R-Ibrutinib (ENRICH) as first line treatment in elderly patients with mantle cell lymphoma. Completed

Chairman and principal investigator of randomized phase IIb multicenter study with Betalutin radioimmunotherapy (PARADIGME) in relapsed follicular lymphoma. Ongoing

Chairman and principal investigator of phase I/II multicenter study with Betalutin radioimmunotherapy followed by rituximab maintenance (ARCHER-1) in relapsed follicular non-Hodgkin's lymphoma. Completed

Chairman and principal investigator of exploratory single center study with sequential intranodal immunotherapy combined with anti-PD-1 antibody (Lymvac-2) in follicular lymphoma. Completed.

National coordinating investigator for multicenter study with CAR19-T cell therapy in relapsed follicular lymphoma (ELARA). Published

Principal investigator for Norwegian multicentre study of Covid-19 vaccination in lymphoma patients. Published

9th of May, 2022

Arne K. Isstad

MD/Professor